If you wish to remain on Xanax but eliminate current Xanax withdrawal side effects, click here.
If you want to taper off the Xanax and you are not sure where to start, you can click here and read the bestselling book, How to Get Off Psychoactive Drugs Safely or send Jim Harper an email at [email protected] and he will guide you through the process of Xanax withdrawal.
If You Are Already In Xanax Withdrawal click here
Xanax is a prescription medication in the class of drugs known as benzodiazepines. It is commonly used to treat anxiety, panic attacks, and insomnia. Like many other benzodiazepines, Xanax is highly addictive, and prolonged use can lead to physical dependence. Withdrawal from Xanax can be difficult and uncomfortable, and it is essential to seek professional help when stopping the medication.
You are on The Road Back Program reading this information. We have helped people off Xanax for the past 23 years. Over 19 million have used this program to become drug free. If you click the link above, Program, you have access to Jim Harper’s bestselling book, How to Get Off Psychoactive Drugs for free. You can also send us an email at the Contact Us link and we can guide you through the Xanax withdrawal process.
Symptoms of Xanax withdrawal can vary depending on the length of time the drug has been used and the dose taken. Some common symptoms of Xanax withdrawal include anxiety, irritability, restlessness, insomnia, tremors, sweating, rapid heartbeat, and muscle spasms. More severe symptoms can include seizures, hallucinations, and delirium.
The severity of the withdrawal symptoms can be influenced by several factors, such as the dose of the drug, duration of use, and individual factors like age, health status, and co-occurring mental health conditions. Generally, the higher the dose and the longer the duration of use, the more severe the withdrawal symptoms.
The withdrawal process from Xanax should be carried out under medical supervision to manage symptoms and prevent complications. Abruptly stopping valium use is not recommended as it can cause severe withdrawal symptoms. The medical professional will gradually reduce the dose of the medication over a period of time, and the patient will be monitored for any potential complications.
The timeline for Xanax withdrawal can vary depending on individual factors, but it usually takes several weeks to months to complete the process. The first few days of withdrawal can be the most difficult as the patient may experience intense withdrawal symptoms. As the withdrawal process continues, the symptoms will gradually decrease in severity and frequency. The Road Back Program is designed to help reduce these side effects and some people will not experience any withdrawal.
There are several medications that may be used during the Xanax withdrawal process to manage symptoms and ease the transition but this is not advised. These medications may include other benzodiazepines, such as diazepam, clonazepam, and lorazepam. Antidepressants and anticonvulsants may also be used to manage specific withdrawal symptoms.
In addition to medication, counseling and therapy can be beneficial during the withdrawal process. Counseling can help patients manage the emotional and psychological aspects of withdrawal and develop coping strategies for long-term recovery.
It is essential to note that valium withdrawal can be a challenging process, and relapse is common. A comprehensive treatment plan that includes medical, psychological, and social support is essential for successful long-term recovery.
In conclusion, valium withdrawal can be a challenging process, and it is essential to seek professional help when stopping the medication. Withdrawal symptoms can vary in severity and duration and can be managed with medical supervision and appropriate nutritional supplements. Counseling and therapy can also be helpful in managing the emotional and psychological aspects of withdrawal. With the right support and treatment, successful recovery is possible.
1. FDA drug label Xanax (alprazolam tablets) Revised 2016 [cited 2023 May 24]
2. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005 May;18(3):249-55. doi: 10.1097/01.yco.0000165594.60434.84. PMID:16639148. [cited 2023 May 24]
3. Connecticut Gvt. Department of Consumer Protection Information “Aprazolam” [cited 2023 May 24]
4. FDA information, “Finding and Learning About Side Effects (adverse reactions).” 2018 July 19 [cited 2023 May 24]
5. DailyMed prescription drug information, “Alprazolam” NIH publication Mar 21, 2021 [cited 2023 May 24]
6. Ashton H, “Benzodiazepines – How they Work and How to Withdraw” aka “The Ashton Manual” [revised Aug 2002] [cited 2023 May 24]
7. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet. 1989 Jun;16(6):337-64. doi: 10.2165/00003088-198916060-00002. PMID: 2567646. [cited 2023 May 24]
8. Browne JL, Hauge KJ. A review of alprazolam withdrawal. Drug Intell Clin Pharm. 1986 Nov;20(11):837-41. doi: 10.1177/106002808602001102. PMID: 3536383.[cited 2023 May 24]
9. Bosshart H. Withdrawal-induced delirium associated with a benzodiazepine switch: a case report. J Med Case Rep. 2011 May 26;5:207. doi: 10.1186/1752-1947-5-207. PMID: 21615891; PMCID: PMC3117827. [cited 2023 May 24]
10. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986 Oct 2;315(14):854-9. doi: 10.1056/NEJM198610023151403. PMID: 3092053. [cited 2023 May 24]
11. O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:28-33. PMID: 15762817. [cited 2023 May 24]
12. Kang M, Galuska MA, Ghassemzadeh S. Benzodiazepine Toxicity. [Updated 2021 Jul 1]. In: StatPearls Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482238/ [cited 2023 May 24]
13. Ananth J. Benzodiazepines: selective use to avoid addiction. Postgrad Med. 1982 Oct;72(4):271-6. doi: 10.1080/00325481.1982.11716231. PMID: 6126869. [cited 2023 May 24]
14. Schmitz A. Benzodiazepine use, misuse, and abuse: A review. Ment Health Clin. 2016;6(3):120-126. Published 2016 May 6. doi:10.9740/mhc.2016.05.120 [cited 2023 May 24]
15. Temte V, Kjeldstadli K, Bruun LD, Birdal M, Bachs L, Karinen R, Middelkoop G, Øiestad E, Høiseth G. An Experimental Study of Diazepam and Alprazolam Kinetics in Urine and Oral Fluid Following Single Oral Doses. J Anal Toxicol. 2019 Mar 1;43(2):104-111. doi: 10.1093/jat/bky062. PMID: 30517712. [cited 2023 May 24]
16. Santo L, Rui P, Ashman J, “Physician Office Visits at which Benzodiazepines were Prescribed: Findings from 2014-2016 National Ambulatory Medical Care Survey” CDC national Health Statistics Reports #137 January 17,2020 [cited 2023 May 24]
17. Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues Clin Neurosci. 2011;13(4):413-421. doi:10.31887/DCNS.2011.13.4/cotte [cited 2023 May 24]
18. DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci. 2008;9(10):788-796. doi:10.1038/nrn2345 [cited 2023 May 24]
19. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav Res Ther. 2010 Aug;48(8):720-7. doi: 10.1016/j.brat.2010.04.002. Epub 2010 Apr 28. PMID: 20546699; PMCID: PMC5962448. [cited 2023 May 24]
20. He Q, Chen X, Wu T, Li L, Fei X. Risk of Dementia in Long-Term Benzodiazepine Users: Evidence from a Meta-Analysis of Observational Studies. J Clin Neurol. 2019;15(1):9-19. doi:10.3988/jcn.2019.15.1.9 [cited 2023 May 24]
21. Statistical Report “The Top 300 of 2021” published online by Clincalc Database [cited 2023 May 24]
22. CDC statistics report published August 2021, Fatal and Nonfatal Overdoses Benzodiazepines [cited 2023 May 24]
23. Genuis SJ. Toxic causes of mental illness are overlooked. Neurotoxicology. 2008 Nov;29(6):1147-9. doi: 10.1016/j.neuro.2008.06.005. Epub 2008 Jun 24. PMID: 18621076. [cited 2023 May 24]
24. Swedish Council on Health Technology Assessment. Treatment of Anxiety Disorders: A Systematic Review Stockholm: Swedish Council on Health Technology Assessment (SBU); 2005 Nov. SBU Yellow Report No. 171/1+2. PMID: 28876726. [cited 2023 May 24]
25. Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse, and Withdrawal. J A Med. 2018;12(1):4-10. doi:10.1097/ADM.0000000000000350 [cited 2023 May 24]
26. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry. 1988 May;45(5):429-36. doi: 10.1001/archpsyc.1988.01800290043006. PMID: 3282479. [cited 2023 May 24]
27. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF. Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry. 1987 Mar;144(3):303-8. doi: 10.1176/ajp.144.3.303. PMID: 3826428. [cited 2023 May 24]
28. Laegreid L, Olegård R, Walström J, Conradi N. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr. 1989 Jan;114(1):126-31. doi: 10.1016/s0022-3476(89)80619-5. PMID: 2562851.[cited 2023 May 24]
29. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990 May;51(5):206-9. PMID: 2335496. [cited 2023 May 24]
30. Pétursson H. The benzodiazepine withdrawal syndrome. Add. 1994 Nov;89(11):1455-9. doi: 10.1111/j.1360-0443.1994.tb03743.x. PMID: 7841856. [cited 2023 May 24]
31. Goffinet S. Mécanisme d’action, indications et abus des benzodiazépines anxiolytiques [Mechanism of action, indications and abuse of benzodiazepine anxiolytic drugs]. Ann Med Psychol (Paris). 1993 Jan;151(1):47-63. French. PMID: 7905724. [cited 2023 May 24]
32. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry. 1987 Dec;48 Suppl:12-6. PMID: 2891684. [cited 2023 May 24]
33. Peart R, Toxicity, Cognitive Impairment, Long Term Damage, and The Post Withdrawal Syndrome [published online December 2000] [cited 2023 May 24]
34. Perlis RH. Misdiagnosis of bipolar disorder. Am J Manag Care. 2005 Oct;11(9 Suppl):S271-4. PMID: 16232009.[cited 2023 May 24]
35. Boyadzhieva A, Kayhan E. Keeping the Breath in Mind: Respiration, Neural Oscillations, and the Free Energy Principle. Front Neurosci. 2021 Jun 29;15:647579. doi: 10.3389/fnins.2021.647579. PMID: 34267621; PMCID: PMC8275985. [cited 2023 May 24]
36. Saeed SA, Cunningham K, Bloch RM. Depression and Anxiety Disorders: Benefits of Exercise, Yoga, and Meditation. Am Fam Physician. 2019 May 15;99(10):620-627. PMID: 31083878. [cited 2023 May 24]
37. Shah NA, Abate MA, Smith MJ, Kaplan JA, Kraner JC, Clay DJ. Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner. Am J Addict. 2012 Nov;21 Suppl 1:S27-34. doi: 10.1111/j.1521-0391.2012.00298.x. PMID: 23786507.[cited 2023 May 24]